Aaron Kantoff (Medicxi)

A Medicxi-backed start­up looks to tack­le treat­ment-re­sis­tant blood can­cers, and it's go­ing af­ter AML first

In the hard­est-to-treat blood can­cers, re­sis­tance to ther­a­py is an ex­is­ten­tial prob­lem for drug de­vel­op­ers look­ing to per­ma­nent­ly stave off tu­mors. A small biotech is chas­ing an emerg­ing path­way to stop tu­mors’ abil­i­ty to re­sist treat­ment, and its work has caught the eye of a cou­ple of big-name in­vestors.

Kurome Ther­a­peu­tics snared a $15 mil­lion Se­ries A round it will use to iden­ti­fy and de­vel­op a lead pro­gram from its plat­form look­ing at dual in­hibitors of the IRAK1/4 sig­nal­ing path­way and FLT3 pro­tein re­cep­tors on heme blasts to crack treat­ment-re­sis­tant tu­mors, the biotech said Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.